Clinical Therapeutics Journal Impact Factor & Information

Publisher: Elsevier

Journal description

Clinical Therapeutics provides a rapid publication of original reports of recent developments in drug therapy. The journal serves an international audience of research clinicians in academia and industry by quickly disseminating their findings through major biomedical databases.The journal features three sections: Clinical Studies, Review Articles, and Pharmaceutical Economics & Health Policy. Published articles range from pilot studies, which explore new drugs and existing drugs for applications, to large multicenter Phase III and IV trials and postmarketing studies. Audience: Research Clinicians in Academia and Industry, Practicing Physicians, Pharmacologists, and Specialists in Pharmacoeconomics, Outcomes Research and Health Policy.

Current impact factor: 2.59

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.586
2012 Impact Factor 2.23
2011 Impact Factor 2.321
2010 Impact Factor 2.551
2009 Impact Factor 3.25
2008 Impact Factor 3.064
2007 Impact Factor 3.261
2006 Impact Factor 2.893
2005 Impact Factor 3.03
2004 Impact Factor 3.009
2003 Impact Factor 2.67
2002 Impact Factor 3.073
2001 Impact Factor 2.721
2000 Impact Factor 2.069
1999 Impact Factor 1.955
1998 Impact Factor 1.539
1997 Impact Factor 1.045

Impact factor over time

Impact factor
Year

Additional details

5-year impact 2.75
Cited half-life 6.20
Immediacy index 0.59
Eigenfactor 0.02
Article influence 0.83
Website Clinical Therapeutics website
Other titles Clinical therapeutics (Online)
ISSN 0149-2918
OCLC 43029633
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Elsevier

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors pre-print on any website, including arXiv and RePEC
    • Author's post-print on author's personal website immediately
    • Author's post-print on open access repository after an embargo period of between 12 months and 48 months
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Author's post-print may be used to update arXiv and RepEC
    • Publisher's version/PDF cannot be used
    • Must link to publisher version with DOI
    • Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License
    • Publisher last reviewed on 03/06/2015
  • Classification
    ​ green

Publications in this journal

  • Clinical Therapeutics 08/2015; 37(8):e114. DOI:10.1016/j.clinthera.2015.05.326
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Evidence suggests that clinical outcomes for people with type 2 diabetes mellitus can be improved through multifactorial treatment. The key challenges in the successful treatment of type 2 diabetes include maintaining tight glycemic control, minimizing the risk of hypoglycemia, controlling cardiovascular risk factors, and reducing or controlling weight. The aim of the present analysis was to evaluate the cost per patient achieving a composite clinical end point (glycosylated hemoglobin <7%, with no weight gain and no hypoglycemic events) in patients with type 2 diabetes in Quebec, Quebec, Canada, receiving liraglutide 1.2 mg, liraglutide 1.8 mg, thiazolidinedione, sulfonylurea, insulin glargine, sitagliptin, or exenatide. Methods The proportion of patients achieving control was taken from a meta-analysis that was based on the Phase III trial program of liraglutide. Treatment costs, estimated from a health care payer perspective, were calculated on the basis of the trials included in the meta-analysis and captured the study drug, needles, self-monitoring of blood glucose (SMBG) test strips, SMBG lancets, and other antidiabetes medications received. Cost-effectiveness in terms of cost per patient achieving the composite end point (cost of control) was evaluated with an economic model developed in Microsoft Excel. No discounting was applied to cost or clinical outcomes because these were not projected beyond a 1-year time horizon. Sensitivity analyses were performed. Findings Liraglutide 1.8 mg was associated with the lowest number needed to treat, with 3 patients needing to be treated to bring 1 patient to the composite end point. Pioglitazone was associated with the highest number needed to treat, with 17 patients requiring treatment to bring 1 patient to the composite end point. Evaluation of only annual pharmacy costs indicated that liraglutide 1.8 mg was the most costly treatment at Can$2780 per patient per year. Pioglitazone and glimepiride were associated with the lowest direct annual costs. Combining the clinical efficacy data with the annual cost of medications produced cost of control values of Can$6070 (liraglutide 1.2 mg), Can$6949 (liraglutide 1.8 mg), Can$7237 (glimepiride), Can$7704 (exenatide), Can$8297 (insulin glargine), Can$8741 (pioglitazone), and Can$9270 (sitagliptin) per patient achieving the composite end point. Implications Liraglutide 1.2 mg and 1.8 mg were associated with the lowest cost of control values, driven by the high proportion of patients achieving the composite end point, which offset the higher medication costs. A relatively low cost of control value was achieved for glimepiride, driven by low acquisition costs, despite relatively few patients achieving the composite end point.
    Clinical Therapeutics 07/2015; DOI:10.1016/j.clinthera.2015.05.496
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews the diagnostically challenging presentation of mast cell activation disease (MCAD) and current thoughts regarding interactions between microbiota and MCs. A search for all studies on interactions between mast cells, mast cell activation disease, and microbiota published on pubmed.gov and scholar.google.com between 1960 and 2015 was conducted using the search terms mast cell, mastocyte, mastocytosis, mast cell activation, mast cell activation disease, mast cell activation syndrome, microbiome, microbiota. A manual review of the references from identified studies was also conducted. Studies were excluded if they were not accessible electronically or by interlibrary loan. Research increasingly is revealing essential involvement of MCs in normal human biology and in human disease. Via many methods, normal MCs-present sparsely in every tissue-sense their environment and reactively exert influences that, directly and indirectly, locally and remotely, improve health. The dysfunctional MCs of the "iceberg" of MCAD, on the other hand, sense abnormally, react abnormally, activate constitutively, and sometimes (in mastocytosis, the "tip" of the MCAD iceberg) even proliferate neoplastically. MCAD causes chronic multisystem illness generally, but not necessarily, of an inflammatory ± allergic theme and with great variability in behavior among patients and within any patient over time. Furthermore, the range of signals to which MCs respond and react include signals from the body's microbiota, and regardless of whether an MCAD patient has clonal mastocytosis or the bulk of the iceberg now known as MC activation syndrome (also suspected to be clonal but without significant MC proliferation), dysfunctional MCs interact as dysfunctionally with those microbiota as they interact with other human tissues, potentially leading to many adverse consequences. Interactions between microbiota and MCs are complex at baseline. The potential for both pathology and benefit may be amplified when compositionally variant microbiota interact with aberrant MCs in various types of MCAD. More research is needed to better understand and leverage these interactions. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(5). DOI:10.1016/j.clinthera.2015.02.008
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Patient Protection and Affordable Care Act (ACA) aims to expand coverage to the previously uninsured, improve the quality of coverage, and help eliminate inefficiencies in the health care market. We evaluated the implications of ACA on the drug industry by examining the impact on the “Dinner-for-Three” dynamic in our health care system. We can think of our system as an odd dinner party in which one person pays (the insurer), one orders the meal (the physician), and yet another eats the meal (the patient). This dynamic requires us to examine each stakeholder and how they interact with one another to assess the impact of the ACA. Of the 6.7 million initial exchange enrollees, ~3.8 million subjects were previously uninsured. A higher percentage of these enrollees are using their pharmacy benefit, and they are disproportionately filling prescriptions for specialty drugs relative to those covered in employer-sponsored plans. Formulary designs in exchange plans are passing on higher cost-sharing for prescription drugs to the patient. ACA has also resulted in the development of accountable care organizations (ACOs); these organizations may play a role going forward in the management of drug spending and the development of formularies and protocols that impact drug prescribing. Payers are tightening control over drug spending and are finding physicians and physician groups increasingly less reluctant allies in doing so. Patients are faced by more complexity than ever in the health care system and are expected to take a more active role in responsibly managing the cost of their care. It is increasingly critical that drug manufacturers develop robust value propositions and communicate that value to all stakeholders. They should re-evaluate trial investment decisions and consider changes in price setting, rebates (how much and to whom), copay programs, and physician and patient support programs in light of changing market needs.
    Clinical Therapeutics 03/2015; 15(4). DOI:10.1016/j.clinthera.2015.02.013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Avibactam is a novel non-β-lactam β-lactamase inhibitor currently being assessed in combination with ceftazidime, ceftaroline fosamil, and aztreonam. The objectives of this study were to investigate the pharmacokinetics, safety, and tolerability of avibactam in healthy young (aged 18-45 years) and elderly (aged ≥65 years) volunteers of both sexes. This was a Phase I, open-label study in which healthy volunteers aged ≥18 years were enrolled into 4 cohorts: young male, young female, elderly male, and elderly female (n = 8 in each group). Subjects were excluded if they had any condition requiring regular medication or any other relevant conditions. All subjects received a single dose of avibactam 500 mg/100 mL given intravenously over 30 minutes. Pharmacokinetic measurements included Cmax, Tmax, AUC0-∞, plasma clearance, and t½. Within the two age categories the mean age across male and female subjects was well matched. The majority of subjects in the young cohort were black (≥62.5%), whilst the majority of those in the elderly cohorts were white (≥75%). Mean avibactam plasma clearance was similar between the young male, young female, and elderly male cohorts (10.16, 10.34, and 9.82 L/h, respectively), and slightly lower in elderly women (7.98 L/h). Mean Cmax was similar in young male, young female, and elderly female subjects (33.8, 36.9, and 38.4 µg/mL) but lower in elderly male subjects (26.5 µg/mL). Point estimates comparing the ratio of Cmax in male and female subjects over all age groups suggested that Cmax values were 18% lower (90% CI, 30%-5% lower) in male subjects compared with female subjects. Mean AUC0-∞ data were similar between the young male, young female, and elderly male cohorts (49.86, 49.75, and 52.40 µg·h/mL) but higher in elderly women (66.23 µg·h/mL). Point estimates comparing the ratio of AUC0-∞ in elderly and young subjects across both sexes suggested that AUC0-∞ values were 17% higher (90% CI, 5%-31%) in elderly subjects compared with young subjects. The t½ was slightly longer for elderly subjects compared with younger subjects. The most common adverse event was administration/venipuncture site bruising (6 events); all adverse events were mild. No notable differences in pharmacokinetics were observed between the male and female cohorts. The generalizability of the study is limited due to its small sample size. However, the small differences observed between the young and elderly cohorts are not sufficient to warrant dosing adjustments based on age. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(4). DOI:10.1016/j.clinthera.2015.01.009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Laxative-refractory opioid-induced constipation (OIC) is defined as OIC despite using 2 laxatives with a different mechanism of action (based on the Anatomical Therapeutic Chemical Classification System level 4 term [contact laxatives, osmotically acting laxatives, softeners/emollients, enemas, and others]). OIC has a significant impact on the treatment and quality of life of patients with severe chronic pain. This noninterventional, observational, real-life study in Belgium investigated the efficacy of prolonged-release oxycodone/naloxone combination (PR OXN) treatment regarding pain relief and OIC compared with previous prolonged-release oxycodone (PR OXY) treatment for laxative-refractory OIC in daily clinical practice.
    Clinical Therapeutics 03/2015; 34(4). DOI:10.1016/j.clinthera.2015.02.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the past decade, many new classes of drugs have received approval from the US Food and Drug Administration for treatment of type 2 diabetes mellitus, including glucagon-like peptide-1agonists, dipeptidyl peptidase-4 inhibitors, and the sodium-glucose cotransporter-2 inhibitors. Many trials have been performed, and several more are currently ongoing to evaluate these drugs. This review addresses the broad therapeutic and pleiotropic effects of these drugs. The review also discusses the role of these drugs in the treatment paradigm for type 2 diabetes and identifies patients who would be suitable candidates for treatment with these drugs.
    Clinical Therapeutics 03/2015; 37(6). DOI:10.1016/j.clinthera.2015.02.016
  • [Show abstract] [Hide abstract]
    ABSTRACT: Premature newborns present unique challenges for the caregiver. Their clinical fragility and immature immune system places them at increased risk for bacterial and viral infections. Current clinical standard of care mandates invasive phlebotomy to assess an infant for an infection. However, serial blood draws can lead to blood transfusions and the infliction of noxious stimuli to this vulnerable population. Salivary screening for common neonatal morbidities, such as infections, could vastly improve the care for these infants and positively affect their long-term clinical outcomes. Recent technological advancements have improved our ability to detect thousands of proteins and/or microbes from a single salivary sample, making noninvasive assessment in neonates a possibility. This article reviews the clinical applications and challenges associated with integrating salivary analysis for infectious surveillance into the neonatal population. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(3). DOI:10.1016/j.clinthera.2015.02.006
  • Clinical Therapeutics 03/2015; 37(3). DOI:10.1016/j.clinthera.2015.02.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is an aggressive malignancy that has a complex relationship with the host immune system. Immunotherapies have long been a mainstay of melanoma therapy, and advanced therapies continue to be effective in treating this disease. Immune checkpoint blockade has proven to be a novel target in melanoma, with the approval of cytotoxic T-lymphocyte antigen-4 (CTLA-4)-targeted therapy. This review evaluates the role of CTLA-4-targeted therapies in the treatment of metastatic melanoma, with a focus on mechanisms, efficacy, toxicity, and future directions of this therapy. A search was performed in PubMed to identify relevant clinical studies that explored the clinical experience with CTLA-4-targeted therapy in melanoma. Signaling through CTLA-4 causes deactivation of T cells after the initial stimulatory signals. Therapies that block CTLA-4 lead to increased T-cell function and an antitumor response in patients with metastatic melanoma. The adverse event profile of these agents is different from that seen with more traditional cancer therapies and consists of dermatitis, colitis, and other autoimmune toxicities. In addition, the pattern of response is different from that seen with traditional cytotoxic therapies, with some patients experiencing initial progression followed by response and some patients having long-term durable responses. Extensive clinical evidence supports the use of CTLA-4-targeted agents in the treatment of metastatic melanoma. The durability of response seen in patients receiving these agents has changed the landscape for patients with melanoma. Combination therapies and other agents with similar mechanisms warrant further exploration for the treatment of metastatic melanoma. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(4). DOI:10.1016/j.clinthera.2015.02.003
  • Clinical Therapeutics 03/2015; 37(3). DOI:10.1016/j.clinthera.2015.02.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Some researchers have suggested that the popularity of complementary and alternative medicine (CAM) in the United States is due, in part, to the growing cost of conventional medical care. The 2011 National Health Interview Survey is the first population survey that directly asks respondents if they have substituted alternative therapies for prescription medications. The purpose of this study was to estimate the adult prevalence of CAM substitution and to identify factors associated with cost-related CAM use. The sample adult core component of the 2011 National Health Interview Survey (N = 33,014) included a number of questions about prescription medication access and use, including "in the past 12 months, did you use alternative therapies to save money?" We used the Behavioral Model of Health Services Use to identify factors associated with the use of alternative therapies among respondents. Multivariate logistic regression models were used to evaluate factors associated with cost-related CAM use. An estimated 12.3 million adults (5.4% of the population) used alternative therapies to save money in 2011. Women, middle-aged (31-50 years) adults, and residents of the western United States were more likely to engage in CAM substitution, as were smokers, those with activity limitations, and those in fair or poor health. The highest rates of CAM substitution were reported by uninsured adults (11.9%). A sizable number of adults in the United States use alternative therapies because they are cheaper than prescription medications. The health risks of such CAM substitution can be serious, and the phenomenon merits further investigation. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(5). DOI:10.1016/j.clinthera.2015.01.014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minodronic acid is a third-generation bisphosphonate being developed for the treatment of osteoporosis. The aim of this study was to evaluate the pharmacokinetic profiles and tolerability of minodronic acid in healthy subjects, as well as to assess the effects of food and age on the pharmacokinetics. This single-center, open-label, Phase I study was conducted in 4 parts. In part 1, minodronic acid tablets were administered to young volunteers at doses of 1, 2, and 4 mg. In part 2, after a single dose, young volunteers in the 1-mg dose group received repeated oral doses of minodronic acid once daily for 7 days. In part 3, a single oral dose of minodronic acid 1 mg was administered to elderly volunteers. In part 4, after a washout period of 8 days, volunteers in the 4-mg group received a single dose of 4-mg minodronic acid under fed conditions (administrated 30 minutes before a high-fat breakfast). Plasma samples were collected, and plasma concentrations of minodronic acid were analyzed by using a LC-MS/MS method. Tolerability was assessed throughout the study by physical examinations, measurement of vital signs, laboratory analyses, and monitoring of adverse events. Thirty-six young volunteers (mean age, 22.1 years; mean weight, 58.6 kg) and 12 elderly volunteers (mean age, 62.3 years; mean weight, 62.4 kg) were enrolled in the study. After single doses of 1, 2, and 4 mg of minodronic acid, the dose-normalized AUC exhibited dose linearity over the range of 1 to 4 mg in the young subjects. The plasma concentration of minodronic acid reached a steady state on day 7 after oral administration once daily for 7 days, with a mean accumulation ratio of 1.3. After a single dose of minodronic acid 1 mg, plasma Cmax and AUC0-∞ were both 1.8-fold higher compared with those of the young subjects. In the 4-mg dose group, minodronic acid Cmax and AUC0-∞ were reduced by 55% and 72%, respectively, with a high-fat breakfast compared with fasted conditions. No clinically meaningful changes in vital signs, laboratory values, or ECGs were observed. Single dosing of minodronic acid exhibited linear pharmacokinetics over the range of 1 to 4 mg; there was no accumulation after repeated administration. Food, especially high-fat food, reduced the bioavailability of minodronic acid. In addition, the exposure of the drug was increased with age. Minodronic acid seemed to be well tolerated throughout the study. ClinicalTrials.gov Identifier: NCT02295436. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 03/2015; 37(4). DOI:10.1016/j.clinthera.2015.01.015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical diagnostics can be improved by faster and more accessible disease detection. Our laboratory has developed a point-of-service (POS) device capable of rapid, sensitive, automated, and multiplexed biomarker detection that uses human saliva instead of other biofluids. Here, we review the technology that led to the development of this POS device. This POS technology can advance clinical diagnostics by saving time because of faster diagnosis, saving money because of a shorter hospital stay, and ultimately improving clinical care. Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 02/2015; 37(3). DOI:10.1016/j.clinthera.2015.02.004